

The palliative chemotherapy of breast cancer (practice data vs. group data)

G. Innig¹, V. Petersen², H. Eschenburg³, U. Hutzschenreuter⁴, S. Müller-Hagen⁵, A. Schlichting⁶, H.-W. Tessen⁷, Project team of Internal Oncology (PIO)

¹Specialized oncology practice Rheine, ²Specialized oncology practice Heidenheim,

³Specialized oncology practice Güstrow, ⁴Specialized oncology practice Nordhorn,

⁵Specialized oncology practice Hamburg, ⁶rgb Onkologisches Management GmbH Sarstedt,

⁷Specialized oncology practice Goslar

Introduction:

With 18,136 cases in the year 2015, breast cancer is the most common cause of death from cancer for women. Compared to 2005, significantly less women with the principal diagnosis breast cancer have been treated as in-patients in hospitals in 2014 according to DRG statistics: While there were about 151,000 women then, the number dropped to 130,000 women in 2014 (-14 %).

Methods:

The registry ONCOReg contains documentations of 11,396 mamma carcinomas from 132 practices nationwide. The collection of data started in 2003. 10,708 patients with 42,292 therapies are available for analysis. From them, 627 patients with 2,478 therapies from the haematological-oncological practice at Rheine have been documented by an external staff member. This analysis documents the palliative chemotherapies.

Results:

2,697 (group) or 150 (practice) patients received 6,833 or 340 palliative chemotherapies. The median age at start of therapy was 62 (25-91 years). 289 (11.0%) or 23 (15.4%) patients were older than 75 years. 2,574 (97.7%) or 142 (94.7%) had distant metastasis. A maximum of 14 or 7 therapies were administered during 104 or 122 days at median.

Table 1: Therapies (%)

	Per cent (group)	Per cent (practice)
1st-line	100.0	100.0
2nd-line	66.0	63.8
3rd-line	41.1	35.6
4th-line	23.6	16.8

An objective response rate (CR/PR/NC) of 62.7% (group) or 78.0% (practice) was achieved.

Table 2: Response rate (CR/PR/NC in %)

	Per cent (group)	Per cent (practice)
1st-line	73.1	86.6
2nd-line	61.7	76.3
3rd-line	55.1	68.6
4th-line	54.2	39.1

The median overall survival as of initial metastasis is 37.8 (group) or 45.8 months (practice).

Table 3: Median progression free survival (months)

	1st-line	2nd-line
Group	9.8	6.5
Practice	11.0	7.0

Table 4: Median survival as of start of therapy (month)

	1st-line	2nd-line
Group	27.8	18.0
Practice	31.5	15.2

Conclusion:

The results of the registry ONCOReg are constantly published. All participating practices have the chance to receive analyses of their own data.